Ovagen
Biologically active food supplement OVAGEN® is a peptide complex containing amino acids: glutamic
acid, aspartic acid, and leucine, which has a normalizing effect on liver cells.
OVAGEN® is available in tablets or capsules with an active substance content of 0.100 mg.
Clinical trials of OVAGEN® were carried out at the Medical Center of the Saint Petersburg Institute of
Bioregulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Sciences
in patients with chronic hepatitis and oncological patients after a course of radiation or chemotherapy
in the period from October 2005 to February 2006.
OVAGEN® was administered to patients orally 10-15 minutes before meals, 1-2 tablets 2 times a day
for 10-20 days, depending on the severity of the pathological process.
Currently, there is an increase in the number of patients with chronic liver diseases, which are prevalent
mainly in people of working age. Unfavorable social and environmental factors mainly cause them.
Chronic hepatitis is not considered an outcome of an acute infectious process but as a form of the
course of the infectious process (2, 3).
In the treatment of patients with chronic hepatitis, taking into account the pathogenetic mechanisms,
the following conventional therapeutic agents are used (1):
- Drugs that improve the metabolism of liver cells (hepatoprotectors) – (Essentiale, Legalon, Sirepar);
- Stimulants of bile secretion – (Liv-52);
- B group vitamins (B1, B6, B12, ascorbic acid);
- etc.
CLINICAL CHARACTERISTICS OF PATIENTS
Clinical trials were carried out in 40 patients with chronic hepatitis and oncological patients after a
course of chemotherapy, including 25 men and 15 women from 38 to 67 years old (Table 1). In addition
to conventional treatment, patients of the primary group received OVAGEN® - 2 capsules 2 times a
day before meals for 15-20 days. The duration of their disease ranged from 3 to 10 years.
The control group consisted of 34 similar patients who were prescribed only conventional medication.
Distribution of patients by nosological forms, sex and age. Table 1
Diagnosis Age (years) Men Women Total
Chronic persisting hepatitis 38-67 14 6 20
State after chemotherapy course in oncological 50-65 11 9 20
patients
Total: 25 15 40
Most patients complained about pain in the right hypochondrium, general weakness, and rapid
fatigability. 78% of patients had dyspeptic disorders. 55% of patients had hyperbilirubinemia, an
increase in the alanine aminotransferase level, and an increase in the globulin fraction of blood
proteins, mainly due to the M immunoglobulin fraction, which indicates a specific activity of the
chronic inflammatory process.
RESEARCH METHODS
The complaints were assessed subjectively at different times. The following tests were carried
out: general clinical examination of blood and urine, biochemical and immunological blood tests
(determination of immunoglobulins using the Mancini method), and liver ultrasound examination.
RESEARCH RESULTS
After treatment with OVAGEN®, most patients noted a significant increase in energy, appetite, and
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.